Oncocyte amends bylaws to allow President role independent of CEO

Insight Molecular Diagnostics Inc.

Board approved Second Amended and Restated Bylaws effective November 3, 2022.
Amendment permits appointment of a President without requiring the CEO to also serve as President.
Full text of amended bylaws is filed as Exhibit 3.1 to the Form 8-K.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.98

Insight Molecular Diagnostics Inc.: Adopted Second Amended and Restated Bylaws on November 3, 2022, allowing the Company to appoint a President or Presidents without requiring the CEO to also be a President (effective 2022-11-03).

Change: bylaw amendment
Effective: 2022-11-03

Exact text from the filing

On and effective as of November 3, 2022, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) approved and adopted the Second Amended and Restated Bylaws of the Company (the “Bylaws”), pursuant to which the Company may appoint a President or Presidents without requiring that the chief executive officer also be a President.

View on SEC.gov

Browse all governance changes →

Insight Molecular Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031088

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.